The Food and Drug Administration approves Paxlovid to treat COVID-19 in adults; a National Institutes of Health study sheds new light on long COVID-19.

FDA authorizes the first at-home nasal test that detects influenza A and B as well as COVID-19; Moderna reaches a $400 million agreement with the National Institutes of Health.

National Institutes of Health research finds that Black and Hispanic Americans face greater long COVID-19 risks, the CDC says that primary series vaccination protects children ages 3–5 for four months, and Novavax will deliver an additional 1.5 million doses.

New COVID-19 vaccine initiatives seek to address access inequalities, and NIH launches a website where Americans can self-report COVID-19 test results anonymously to provide data to public health departments.

HHS links COVID-19 vaccinations to fewer COVID-19 hospitalizations and deaths, and NIH details its plan to study long COVID-19 effects.

WHO announces new names for SARS-CoV-2 variants of concern; two NIH studies show that mRNA vaccines are safe for pregnant people.

FDA Commissioner Stephen Hahn, MD, says drug and biological product centers will publicly post reviews of the data and information supporting emergency use authorizations (EUAs) for all drug and biological products, including vaccines, as part of the agency's COVID-19 response.

An interim analysis of Moderna Inc.'s COVID-19 vaccine shows promising results; CDC guidance highlights that wearing a mask can protect the wearer.

FDA grants emergency use authorization for an Eli Lilly antibody treatment; a Pfizer vaccine has promising early results; President-elect Biden names a COVID-19 advisory board.

NIH will study experimental COVID-19 treatments and support the development of six new testing technologies; FDA's vaccine committee will meet Oct. 22.

A panel convened by the National Institutes of Health culminated in an evidence report that includes 26 recommendations for improving implementation of proven services to reduce disparities in preventable conditions.

Three essential hospitals will join the National Institutes of Health's Justice Community Opioid Innovation Network to research quality addiction treatment for opioid use disorder in jails, drug courts, and other criminal justice settings.